The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Open accessAbstract
BACKGROUND: Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse events; its effects on cardiovascular outcomes remain uncertain. METHODS: We conducted a double-blind, randomized, placebo-controlled trial involving patients who were unable or unwilling to take statins owing to unacceptable adverse effects ("statin-intolerant" patients) and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. The primary end point was a four-component composite of major adverse cardiovascular events, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization. RESULTS: A total of 13,970 patients underwent randomization; 6992 were assigned to the bempedoic acid group and 6978 to the placebo group. The median duration of follow-up was 40.6 months. The mean LDL cholesterol level at baseline was 139.0 mg per deciliter in both groups, and after 6 months, the reduction in the level was greater with bempedoic acid than with placebo by 29.2 mg per deciliter; the observed difference in the percent reductions was 21.1 percentage points in favor of bempedoic acid. The incidence of a primary end-point event was significantly lower with bempedoic acid than with placebo (819 patients [11.7%] vs. 927 [13.3%]; hazard ratio, 0.87; 95% confidence interval [CI], 0.79 to 0.96; P = 0.004), as were the incidences of a composite of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (575 [8.2%] vs. 663 [9.5%]; hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P = 0.006); fatal or nonfatal myocardial infarction (261 [3.7%] vs. 334 [4.8%]; hazard ratio, 0.77; 95% CI, 0.66 to 0.91; P = 0.002); and coronary revascularization (435 [6.2%] vs. 529 [7.6%]; hazard ratio, 0.81; 95% CI, 0.72 to 0.92; P = 0.001). Bempedoic acid had no significant effects on fatal or nonfatal stroke, death from cardiovascular causes, and death from any cause. The incidences of gout and cholelithiasis were higher with bempedoic acid than with placebo (3.1% vs. 2.1% and 2.2% vs. 1.2%, respectively), as were the incidences of small increases in serum creatinine, uric acid, and hepatic-enzyme levels. CONCLUSIONS: Among statin-intolerant patients, treatment with bempedoic acid was associated with a lower risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization). (Funded by Esperion Therapeutics; CLEAR Outcomes ClinicalTrials.gov number, NCT02993406.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The CLEAR Outcomes trial randomized 13,970 patients with established or high risk for CVD, intolerance to statins, and LDL-C level ≥ 100 mg/dL to receive bempedoic acid (180 mg daily) or placebo [131]. Bempedoic acid reduced the risk of MACE by − 13% (HR 0.87, 95% CI 0.79–0.96, p = 0.004) and resulted in a − 21.1% greater reduction in LDL-C levels”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [133]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is important to note that ∼19% of individuals were on very-low-dose statin therapy at baseline (135).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [135]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This substantially exceeded other oral non-statin therapies, as ezetimibe lowers LDL-C by 18–25%, bempedoic acid by 17–21%, and their combination by ∼36–40% [[21], [22], [23], [24]]”
From Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials (2026) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the CLEAR-Outcomes trial, an intriguing observation was that BA’s relative risk reduction for the primary composite outcome differed significantly between the primary and secondary prevention groups (with hazard ratios of 0.68 versus 0.91 respectively) [7].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A higher frequency of gout (3.1% versus 2.1%) and cholelithiasis (2.2% versus 1.2%) was observed with bempedoic acid than with placebo [133].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [133]
The cited source says what the claim attributes to it.
In the citing paper
“The Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid or Placebo (CLEAR Outcomes) trial found a reduction in four-point major adverse cardiovascular events by 13% compared with placebo for individuals with established ASCVD (70% of population) or at high risk for ASCVD (30% of population) a”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical trials have shown bempedoic acid reduces LDL-C levels and the CLEAR Outcomes trial demonstrated a significant reduction in MACE compared with placebo in patients who are statin intolerant [[12], [13], [14], [15],17].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The CLEAR Outcomes (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) trial reported cardiovascular outcomes in a mixed population of primary and secondary prevention patients unable or unwilling to take guideline-recommended doses of statins.11”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“This primary prevention cohort was a prespecified subgroup that represented 30% of the total enrolled within a larger trial that included a mixed population of primary and secondary prevention patients.11”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“This was followed by recent data from the CLEAR Outcomes trial showing reductions in clinical events [7].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“These differences are likely attributable to a lack of statistical power and imprecise estimates as the largest outcomes-based trial, CLEAR Outcomes, had not yet been published at the time of the previous meta-analyses but is included in our meta-analysis [7].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, most of the trials included in this analysis had relatively short follow-up durations with the exception of CLEAR Outcomes [7] and CLEAR Harmony [12].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The overall risk of bias was low 7 of 11 trials [7, 9–12, 15, 16], with 4 trials being assessed as having a moderate risk of bias [8, 13, 14, 17].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Among the 6992 patients assigned to the active arm of the study 45% had T2DM.Bempedoic acid was associated with a significantly lower incidence of the four-component composite primary endpoint of CV death, non-fatal MI, non-fatal stroke, or coronary revascularization and a higher incidence of some adverse events (gout and cholelithiasis) at the 40.6 month follow-up.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [282]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationStatins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Self-citationStroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Self-citationSafety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807
Self-citationPinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498
Goldberg, A. C., Leiter, L. A., Stroes, E. S. G., Baum, S. J., Hanselman, J. C., Bloedon, L. T., Lalwani, N. D., Patel, P. M., Zhao, X., & Duell, P. B. (2019) · JAMA · doi:10.1001/jama.2019.16585 · Cited by 481
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,000
Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies
Omari, M., & Alkhalil, M. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040126 · Cited by 9
Velidakis, N., Stachteas, P., Gkougkoudi, E., Papadopoulos, C. E., & Kadoglou, N. P. E. (2024) · Pharmaceuticals · doi:10.3390/ph17050568 · Cited by 8
Management and Pharmacological Treatment of Peripheral Arterial Disease
Leatham, S. J., Winckel, K., & Guzman, K. R. D. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241250084 · Cited by 8
Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future
Faluk, M. A., Wardhere, A., Mohamoud, A. A., Nor, M. A., Bampastsias, D., Oikonomou, E., Almubaid, Z., & Hemyari, B. A. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102637 · Cited by 8
Triglycerides and the Risk of Atherosclerotic Cardiovascular Events Across Different Risk Categories
Mizuta, H., Ishii, M., Ikebe, S., Otsuka, Y., Yamanouchi, Y., Nakamura, T., & Tsujita, K. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65334 · Cited by 8
New Approaches to Lipoproteins for the Prevention of Cardiovascular Events
Fujino, M., Giovanni, G. D., & Nicholls, S. J. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22031 · Cited by 8
Self-citationCutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins
Capuozzo, M., Ottaiano, A., Cinque, C., Farace, S., & Ferrara, F. (2025) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2024.12.002 · Cited by 8
Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?
Béliard, S., Mourre, F., & Valéro, R. (2024) · Diabetologia · doi:10.1007/s00125-024-06100-z · Cited by 8
Dix, C. H. K., Dolan, G., & Hunt, B. J. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.01.017 · Cited by 7
Bellosta, S., & Corsini, A. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2402493 · Cited by 8
Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease
Hurwitz, M., Agboola, O. J., Gami, A., Williams, M. S., Virani, S. S., Sharma, G. V., & Patel, J. (2025) · US Cardiology Review · doi:10.15420/usc.2024.33 · Cited by 10
Treatment pathways of lipid-lowering therapies in Germany 2016–2022
Katzmann, J. L., Grellmann, C., Leppert, B., Müller-Kozarez, I., Schulz, M., & Laufs, U. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02686-5 · Cited by 7
Association of Uric Acid-Lowering Therapies on Gout Frequency with Bempedoic Acid
Ray, K. K., Nicholls, S. J., Lincoff, A. M., Li, N., Powell, H. A., Herout, P. M., Bloedon, L. T., & Nissen, S. E. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102207 · Cited by 7
Self-citationBrie, D. M., Mornoş, C., Adam, O., Tîrziu, A., & Brie, A. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186445 · Cited by 7
Heydari, F., Hamblin, M. R., & Naghinezhad, J. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01394-3 · Cited by 7
Amore, B. M., MacDougall, D. E., Hanselman, J. C., & Emery, M. G. (2023) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1297 · Cited by 7
Novel Pharmacotherapies for Hyperlipidemia
Reamy, B. V., Ford, B., & Goodman, C. (2023) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2023.08.002 · Cited by 7
Gavilán‐Carrera, B., Soriano‐Maldonado, A., Mediavilla-García, J. D., Lavie, C. J., & Vargas‐Hitos, J. A. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106962 · Cited by 8
Abrahams, T., & Nicholls, S. J. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2292039 · Cited by 8
Self-citationDeaney, C. N., Donaldson, M. P., Reesby, D. M., Scott, V. L., Ellis, V., Cole, G. E., Daly, N. M. C., McKechnie, S. C., Daff, M., Knudsen, S. L., et al. (2024) · Journal of Primary Care & Community Health · doi:10.1177/21501319241236339 · Cited by 7
Miller, M. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001136 · Cited by 7
Monocytic microRNAs—Novel targets in atherosclerosis therapy
Euler, G., & Parahuleva, M. S. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16367 · Cited by 9
Zhang, A. M. C., Ziogos, E., Harb, T., Gerstenblith, G., & Leucker, T. M. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14272 · Cited by 7
Statin alternatives for the treatment of hypercholesterolemia - a safety evaluation
Zeng, W., & Tomlinson, B. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2424411 · Cited by 7
Recomendaciones preventivas vasculares. Actualización PAPPS 2024
Orozco‐Beltrán, D., Brotons-Cuixart, C., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Martín-Rioboó, E., Jordá-Baldó, A., Vicuña, J., & Navarro-Pérez, J. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103123 · Cited by 9
Wierzbicki, A. S. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2444986 · Cited by 8
LDL cholesterol as a causal agent of atherosclerosis
Pedro‐Botet, J., Climent, E., & Benaiges, D. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100728 · Cited by 7
Stürzebecher, P. E., Katzmann, J. L., Gouni-Berthold, I., Mateev, C., Frenzel, O., Schatz, U., Baessler, A., Köenig, W., Schirmer, S. H., Müller-Kozarez, I., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100953 · Cited by 7
Razavi, A. C., Troy, A. L., Patel, J., Mehta, L. S., Spitz, J. A., Lloyd‐Jones, D. M., Whelton, S. P., Johansen, M. C., & Blumenthal, R. S. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101724 · Cited by 8
Maturation of Lipid Management in the 2025 ACC/AHA Acute Coronary Syndrome Guideline
Brandts, J., & Ray, K. K. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.024 · Cited by 7
Self-citationMohan, G. V. K., Chenna, V. S. H., Tirumandyam, G., Mian, A. R., Rashid, A., & Saleem, F. (2023) · Cureus · doi:10.7759/cureus.38662 · Cited by 7
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review
McClintick, D. J., & Giugliano, R. P. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000897 · Cited by 7
Regulation of cholesterol metabolism: New players for an old physiological process
Parente, M., Tonini, C., Segatto, M., & Pallottini, V. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30477 · Cited by 7
Escobar, C., Barrios, V., Cequier, A. R., Cosı́n-Sales, J., Seijas‐Amigo, J., Gómez‐Doblas, J. J., Arrarte, V., Tuñón, J., & Banach, M. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.10.002 · Cited by 7
Ray, K. K., Gunn, L. H., Conde, L. G., Raal, F. J., Wright, R. S., Gosselin, N. H., Leiter, L. A., Köenig, W., Schwartz, G. G., & Landmesser, U. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117472 · Cited by 8
Self-citationLifestyle Approach and Medical Therapy of Lower Extremity Peripheral Artery Disease
Krittanawong, C., Escobar, J., Virk, H. U. H., Alam, M., Virani, S. S., Lavie, C. J., Narayan, K. M. V., & Sharma, R. M. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.10.028 · Cited by 7
Ray, K. K., Bloedon, L. T., Li, N., & Nissen, S. E. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00063-9 · Cited by 7
Self-citationHamayal, M., Shahid, W., Akhtar, C. H., Shekiba, F., Iftikhar, I., Tahir, M. D., Awwab, M., Hussain, S., Naeem, S., & Hafeez, M. (2024) · Future Cardiology · doi:10.1080/14796678.2024.2388478 · Cited by 6
Zhang, L., Hu, W., Guo, H., Sun, Q., Xu, X. J., Li, Z., Qiu, Z., & Bian, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00260 · Cited by 6
Roger, G., Packard, C. J., Masana, L., Laufs, U., Catapano, A. L., & Steg, P. G. (2025) · Heart · doi:10.1136/heartjnl-2025-325765 · Cited by 6
Multiplicity Control in Clinical Trials
Lalonde, A., & Nissen, S. E. (2025) · NEJM Evidence · doi:10.1056/evidctw2400393 · Cited by 6
Self-citationLipoprotein apheresis: Current overview and future outlook in clinical practice
Schettler, V. J. J. (2025) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2025.104209 · Cited by 7
Miteva, K., Buhayer, A., Follonier, C., & Mach, F. (2025) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001777 · Cited by 6
Banach, M., Toth, P. P., Ahn, H., Bielecka-Dabrowa, A. M., Cicero, A. F. G., Covic, A. C., Dalakoti, M., Escobar, C., Fogacci, F., Gaiță, D. I., et al. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.11.003 · Cited by 8
Lipoprotein(a) – treatments in development
Tomlinson, B., & Law, C. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601062 · Cited by 6
Acute Coronary Syndromes: State-of-the-Art Diagnosis, Management, and Secondary Prevention
Yuan, X., Nienaber, S., Akin, I., Kabir, T., & Nienaber, C. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010016 · Cited by 6
Tanaka, A., Oyama, K., Yakushiji, Y., Natsuaki, M., Mizuno, A., Saito, Y., Matsumoto, S., Yamagami, H., Kunieda, T., Shibata, S., et al. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65908 · Cited by 6
Pradhan, A. K., Thandi, P., Mahajan, K., Iellamo, F., Perrone-Filardi, P., & Perrone, M. A. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.059 · Cited by 6
MASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 6
Familial Hypercholesterolemia: From Clinical Suspicion to Novel Treatments
Mirzai, S., Chevli, P. A., Rikhi, R. R., & Shapiro, M. D. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2411311 · Cited by 8
Bolt, L., Speierer, A., Bétrisey, S., Aeschbacher‐Germann, M., Blum, M. R., Gencer, B., Giovane, C. D., Aujseky, D., Moutzouri, E., & Rodondi, N. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297852 · Cited by 6
Advances in familial hypercholesterolemia
Paquette, M., & Baass, A. W. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.02.004 · Cited by 6
Ермоленко, В. М. (2024) · Nephrology (Saint-Petersburg) · doi:10.36485/1561-6274-2024-28-1-13-29 · Cited by 6
Primary Prevention of Cardiovascular Disease in Women
Shahid, I., Avenatti, E., Titus, A., Al-Kindi, S. G., & Nasir, K. (2024) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1313 · Cited by 7
Nicholls, S. J., & Nelson, A. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362644 · Cited by 6
Self-citationReview of Recent Literature and Updates in Nonstatin Cholesterol Management
Wang, E. M., Asias-Dinh, B. D., & Rosario, N. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.03.001 · Cited by 6
An up-to-date review of emerging biologic therapies for hypercholesterolemia
Tomlinson, B. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2442455 · Cited by 6
Chandra, A. A., Espiche, C., Maliha, M., Virani, S. S., Blumenthal, R. S., Rodríguez, F., Wong, N. D., Gulati, M., Slipczuk, L. N., & Shapiro, M. D. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100919 · Cited by 6
Nguyen, N., & Michelis, K. C. (2025) · US Cardiology Review · doi:10.15420/usc.2024.34 · Cited by 7
Yamashita, S., Fujita, H., Yokota, D., Isogai, Y., & Kitamoto, R. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65336 · Cited by 6
Molecular targets of bempedoic acid and related decoy fatty acids
Supplee, J., Marmorstein, R., & Wellen, K. E. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.04.002 · Cited by 6
Trends in Lipid‐Lowering Agent Consumption in Croatia: A 25‐Year Observational Study
Belančić, A., Štiglić, M. K., Prgomet, L., Pećin, I., Reiner, Ž., & Vitezić, D. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70122 · Cited by 6
2024 KSoLA Update on New Lipid-Lowering Agents: Inclisiran and Bempedoic Acid
Kim, H., Cha, J., & Lee, S. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.2.135 · Cited by 6
Bhatty, A., Wilkinson, C., Aktaa, S., Batra, G., Beska, B., Khaing, P. H., Wahab, A., Raveendra, K., Taha, A., Nadarajah, R., et al. (2025) · Heart · doi:10.1136/heartjnl-2025-326045 · Cited by 6
Cardiovascular risk management beyond statins: review of new therapies available in Italy
Capuozzo, M., Ottaiano, A., Cinque, C., Farace, S., & Ferrara, F. (2025) · The Egyptian Heart Journal · doi:10.1186/s43044-025-00660-0 · Cited by 7
Pushing the limits of LDL cholesterol: Emerging paradigms in cardiovascular risk reduction
Yaghoubi, D., & Sallam, T. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.07.002 · Cited by 6
Statin Discontinuation After Coronary Revascularization
Yamamoto, K., Morimoto, T., Natsuaki, M., Shiomi, H., Ogita, M., Tada, T., Toyota, T., Nakatsuma, K., Ehara, N., Yamaji, K., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.09.047 · Cited by 6
Alunno, A., Carubbi, F., Campanozzi, E., Bellisario, F., Schoones, J. W., Mariani, F. M., Ruscio, E. D., Altieri, P., & Ferri, C. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1234601 · Cited by 6
Lee, Y., Lee, S., You, S. C., Lee, Y., Lee, S., Hong, S., Ahn, C., Kim, B., Ko, Y., Choi, D., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15374 · Cited by 6
Racial and Ethnic Disparities in the Management of Chronic Coronary Disease
Tang, W. L., & Rodríguez, F. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.11.008 · Cited by 6
Schreiner, T. G., Ignat, B. E., Grosu, C., Costache, A. D., Leon, M. M., & Mitu, F. (2024) · Medicina · doi:10.3390/medicina60040561 · Cited by 6
Lipid-lowering approaches to manage statin-intolerant patients
Ruscica, M., Bertoletti, A., Gobbi, C., Sirtori, C. R., Carugo, S., & Corsini, A. (2024) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae007 · Cited by 6
Gillard, K. K., Bloedon, L. T., Grady-Benson, J. C., Edwards, A., Fahy, S., Sasiela, W. J., Louie, M. J., & Thompson, P. D. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00374-5 · Cited by 6
Self-citationDiamond, D. M., & Leaverton, P. E. (2023) · Cureus · doi:10.7759/cureus.38391 · Cited by 7
Low‐density lipoprotein cholesterol cannot be too low after a myocardial infarction
Wulff, A. B., Mortensen, M. B., & Nordestgaard, B. G. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13694 · Cited by 6
Mosaad, M., El-Sayed, E. K., & Morsy, E. M. E. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04047-5 · Cited by 5
Labinaz, A., Yao, R., Hosseini, F., Turgeon, R. D., Marchand, M., Brunham, L. R., Hawkins, N. M., Wong, G. C., Mancini, G. B. J., & Fordyce, C. B. (2025) · CJC Open · doi:10.1016/j.cjco.2025.06.021 · Cited by 5
Diagnosis and Management of Statin-Associated Muscle Symptoms
Cha, J., & Hong, S. J. (2025) · Korean Circulation Journal · doi:10.4070/kcj.2025.0285 · Cited by 5
Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5
Ruhela, N., Singla, A., Trivedi, Y. V., Ahmed, M., Chikatimalla, R., Gupta, S., & Jain, R. (2025) · Coronary Artery Disease · doi:10.1097/mca.0000000000001574 · Cited by 5
Dysregulated Lipid Metabolism as a Central Driver of Atherosclerotic Plaque Pathology
Steinbeck, J. E., Iannotti, R. A., & Rasheed, A. (2025) · Lipidology · doi:10.3390/lipidology2040017 · Cited by 5
Drexel, H., Festa, A., Schmidt, T. A., Rocca, B., Dobrev, D., Agewall, S., Tamargo, J. L., & Kaser, S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf076 · Cited by 6
Focused update 2025 delle linee guida ESC/EAS 2019 per il trattamento delle dislipidemie
Mach, F., Koskinas, K. C., van Lennep, J. E. R., Tokgözoğlu, L. S., Badimón, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., Backer, G. D., et al. (2025) · Giornale italiano di cardiologia · doi:10.1714/4586.45945 · Cited by 5
Petsas, E., Kiouri, D. P., Georgiou, N., Siasos, G., Mavromoustakos, T., & Chasapis, C. T. (2025) · Molecules · doi:10.3390/molecules30214240 · Cited by 6
Ray, K. K., & Kronenberg, F. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120636 · Cited by 5
Self-citationWhite, R. T., Ansong, B. O., & Cowart, K. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.02.014 · Cited by 5
Bempedoic Acid and Venous Thromboembolism Risk Among Statin-Intolerant Patients
Spiazzi, B. F., Brennan, D. M., Zingano, C. P., Powell, H. A., Nicholls, S. J., Nissen, S. E., & Laffin, L. J. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.1208 · Cited by 5
Self-citationNew and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering
Gaudet, D., Larouche, M., Raal, F. J., & Catapano, A. L. (2026) · Circulation Research · doi:10.1161/circresaha.126.327270 · Cited by 5
Interventions for the prevention and management of cardiometabolic multiple long-term conditions
Valabhji, J., Hope, D. C. D., SAYED, N. A. E., Godia, P., Lawson, C. A., Seidu, S., & Khunti, K. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00608-2 · Cited by 5
Bottino, R., Carbone, A., Formisano, T., D’Elia, S., Orlandi, M., Sperlongano, S., Molinari, D., Castaldo, P., Palladino, A., Barbareschi, C., et al. (2023) · Life · doi:10.3390/life13071552 · Cited by 5
Optimal Medical Therapy for Stable Ischemic Heart Disease in 2024
Abrahams, T., Nicholls, S. J., & Nelson, A. J. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.12.005 · Cited by 5
Self-citationQureshi, Z. A., Khanzada, M., Safi, A., Fatima, E., Altaf, F., & Vittorio, T. J. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001945 · Cited by 5
Lipid clinic experience with bempedoic acid in three UK centres
Jakubowska, A., Al Hasani, W., Williams, J., MacMahon, Z., Balbas, B., Crook, M. A., Viljoen, A., Reynolds, T. M., & Wierzbicki, A. S. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2341870 · Cited by 5
Li, B., Zhang, J., Huang, A., Chen, Y., & Wei, Q. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132305 · Cited by 7
2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy?
Galli, M., Gragnano, F., Vrints, C. J., & Andreotti, F. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae069 · Cited by 5
Taha, H., Kandil, H., Badran, H. M., Farag, N. M., Khamis, H., Nasr, G. M., Samy, M., Abdrabou, M., Abuelezz, M., & Shaker, M. M. (2024) · The Egyptian Heart Journal · doi:10.1186/s43044-024-00562-7 · Cited by 5
Chen, M., Little, P. J., Kong, S., Banach, M., Weng, J., & Xu, S. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.10.008 · Cited by 6
Lai, P., Xu, S., Liu, Z., Ling, J., Tian, K., Yan, J., Chen, D., Zhong, Y., & Xue, J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1474472 · Cited by 5
Perspectives in the Diagnosis, Clinical Impact, and Management of the Vulnerable Plaque
Alperi, A., Antuña, P., Almendárez, M., Álvarez‐Velasco, R., del Valle-Fernández, R., Pascual, I., Hernández‐Vaquero, D., & y, P. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051539 · Cited by 5
Li, L., Wang, Y., Du, Z., Yu, H., Yang, Y., Zhang, Z., Duan, Y., Han, L., Hu, C., Du, Y., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156417 · Cited by 5
Metadata
- Authors
- Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., Bays, H. E., Moriarty, P. M., Menon, V., Grobbee, D. E., Louie, M. J., Chen, C.-F., Li, N., Bloedon, L., Robinson, P., Horner, M., Sasiela, W. J., McCluskey, J., Davey, D., Fajardo-Campos, P., Petrovic, P., Fedacko, J., Zmuda, W., Lukyanov, Y., & Nicholls, S. J.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cleveland Clinic, Cleveland (S.E.N., A.M.L., D.B., D.M., L.C., V.M., J.M., D.D.); Imperial College London, London (K.K.R.); University of Amsterdam Academic Medical Center, Amsterdam (J.J.P.K.), and University Medical Center Utrecht, Utrecht (D.E.G.) — both in the Netherlands; Hartford Hospital, Hartford, CT (P.D.T.); Brigham and Women’s Hospital, Harvard Medical School, Boston (P.L., J.P.); Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY (H.E.B.); University of Kansas Medical Center, Kansas City (P.M.M.); Esperion Therapeutics, Ann Arbor, MI (M.J.L., C.-F.C., N.L., L.B., P.R., M.H., W.J.S.); Centro de Investigación Cardiovascular y Metabólica, Tijuana, Mexico (P.F.-C.); General Hospital Sveti Luka, Smederevo, Serbia (P.P.); Center of Clinical and Preclinical Research Medipark, Pavol Jozef Šafárik University, Košice, Slovakia (J.F.); Medicome, Oświęcim, Poland (W.Z.); Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia (Y.L.); and Victorian Heart I...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-04-13
- Volume
- 388
- Issue
- 15
- Pages
- 1353-1364
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4323075797
- Semantic Scholar
- 33b876475ba15ddd5ffc66ad5046afe4cb9173b0
- Cited by
- 988
- References
- 21
- Citations by year
- 2026: 266 · 2025: 261 · 2024: 270 · 2023: 189
- FWCI
- 263.23
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Esperion Therapeutics
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- bempedoic acid, statin intolerance, ATP-citrate lyase inhibitor, LDL cholesterol lowering, major adverse cardiovascular events, cardiovascular disease prevention, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, stroke, coronary revascularization, hypercholesterolemia, lipid-lowering therapy, statin adverse effects
- MeSH terms
- Administration, Oral, Hypolipidemic Agents, Cardiovascular Diseases, Dicarboxylic Acids, Double-Blind Method, Fatty Acids, Humans, Myocardial Infarction, Myocardial Revascularization, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
